Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Amgen Inc | 144 |
| 2 | Infinity Pharmaceuticals Inc | 111 |
| 3 | Revolution Medicines Inc | 104 |
| 4 | University of Michigan (System) | 58 |
| 5 | Kura Oncology Inc | 52 |
| 6 | Merck Sharp & Dohme LLC | 41 |
| 7 | Sumitomo Pharma Oncology Inc | 27 |
| 8 | Taiho Pharmaceutical Co Ltd | 25 |
| 9 | Sony Group Corp | 23 |
| 10 | Institut National de la Santé et de la Recherche Médicale | 22 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 1,207 |
| 2 | A61K | Medicinal preparations | 1,081 |
| 3 | C07D | Heterocyclic compounds | 893 |
| 4 | C07K | Peptides | 259 |
| 5 | C07B | General methods of organic chemistry | 160 |
| 6 | C07F | Organometallic compounds | 138 |
| 7 | Y02A | Climate change adaptation | 120 |
| 8 | G01N | Investigating / analysing materials | 83 |
| 9 | C12N | Microorganisms, enzymes | 80 |
| 10 | C12Q | Measuring/testing involving enzymes | 56 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| 4-Imino-1,3-diazabicyclo-(3.1.0)-hexan-2-one as a cancerostat and immuno-stimulant | 1978 | Roche Diagnostics GmbH | 14 |
| Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon | 1994 | Roche Diagnostics GmbH | 7 |
| Use of imexone as an immunosuppressive agent | 1990 | Roche Diagnostics GmbH | 2 |
| Use of imexon as immunosuppressant | 1990 | BOEHRINGER MANNHEIM GMBH, 6800 MANNHEIM, DE | 2 |
| PROCESS FOR PRODUCING IMMUNOSUPPRESSIVE PHARMACEUTICAL COMPOSITIONS COMPRISING IMEXON | 1990 | BOEHRINGER MANNHEIM GMBH.,DE | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Synthesis and biological activity | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Robert T. Dorr | University of Arizona | 21 |
| 2 | Evan M. Hersh | University of Arizona | 10 |
| 3 | Betty K. Samulitis | University of Arizona | 9 |
| 4 | Terry H. Landowski | University of Arizona | 9 |
| 5 | Anton Simeonov | National Center for Advancing Translational Sciences | 5 |
| 6 | Ajit Jadhav | National Center for Advancing Translational Sciences | 4 |
| 7 | Claire M. Payne | University of Arizona | 4 |
| 8 | John D. Morrey | Utah State University | 4 |
| 9 | Kevin M. Okleberry | Utah State University | 4 |
| 10 | Bastiaan Nuijen | The Netherlands Cancer Institute | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities | 2009 | 457 | Retinoids in leukemia and cellular processes |
| Induction of mitochondrial changes in myeloma cells by imexon | 2001 | 92 | Drug Transport and Resistance Mechanisms |
| Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon | 2000 | 90 | Synthesis and Catalytic Reactions |
| Phase I Trial of Imexon in Patients With Advanced Malignancy | 2007 | 56 | Synthesis and biological activity |
| Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent | 2004 | 54 | Drug Transport and Resistance Mechanisms |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical structure and molecular formula of Imexon?
Which organizations hold the most patents related to Imexon?
What are the primary research topics associated with Imexon in published literature?
Who are the most prolific authors publishing research on Imexon?
What patent technology classifications are most relevant to Imexon patents?